245 related articles for article (PubMed ID: 12053418)
1. Health technology assessment. The pharmaceutical industry perspective.
Schubert F
Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
[TBL] [Abstract][Full Text] [Related]
2. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
3. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
4. Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective.
Hillock NT; Merlin TL; Karnon J; Turnidge J; Eliott J
Int J Technol Assess Health Care; 2020 Nov; 37():e28. PubMed ID: 33138869
[TBL] [Abstract][Full Text] [Related]
5. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
6. STAKEHOLDER INVOLVEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN LATIN AMERICA.
Pichon-Riviere A; Soto N; Augustovski F; Sampietro-Colom L
Int J Technol Assess Health Care; 2018 Jan; 34(3):248-253. PubMed ID: 29888698
[TBL] [Abstract][Full Text] [Related]
7. Early dialogue with health technology assessment bodies: a European perspective.
Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
[TBL] [Abstract][Full Text] [Related]
8. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
Fischer KE; Heisser T; Stargardt T
Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
[TBL] [Abstract][Full Text] [Related]
11. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
[TBL] [Abstract][Full Text] [Related]
12. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
14. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
[TBL] [Abstract][Full Text] [Related]
15. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
Taylor R
Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
[TBL] [Abstract][Full Text] [Related]
16. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
Oortwijn W; Mathijssen J; Banta D
Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
[TBL] [Abstract][Full Text] [Related]
17. Defining the scope of health technology assessment and types of health economic evaluation.
Tanvejsilp P; Ngorsuraches S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S10-6. PubMed ID: 24964694
[TBL] [Abstract][Full Text] [Related]
18. Differences among formulary submission guidelines: implications for health technology assessment.
Mauskopf J; Walter J; Birt J; Bowman L; Copley-Merriman C; Drummond M
Int J Technol Assess Health Care; 2011 Jul; 27(3):261-70. PubMed ID: 21756414
[TBL] [Abstract][Full Text] [Related]
19. Improving Access to High-Cost Technologies in the Asia Region.
Mundy L; Trowman R; Kearney B
Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
[TBL] [Abstract][Full Text] [Related]
20. OVERCOMING THE BARRIERS TO ACHIEVING UNIVERSAL HEALTH CARE IN THE ASIAN REGION.
Mundy L; Trowman R; Kearney B
Int J Technol Assess Health Care; 2018 Jan; 34(4):352-359. PubMed ID: 29986782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
